PeproMene Bio is developing BAFF-R CAR-T therapy, a targeted immune treatment designed to address B-cell malignancies and autoimmune disorders by utilizing a novel antibody that specifically targets the B-cell Activating Factor Receptor. This approach aims to improve patient outcomes by overcoming tumor relapse associated with antigen loss, providing a new therapeutic option for those with limited treatment alternatives.
Funding
$50.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with B-cell malignancies and autoimmune disorders often face relapse due to antigen loss following CD19-CAR T cell therapy. The lack of alternative tumor targets contributes to disease recurrence and limits treatment options for these patients.
Solution
PeproMene Bio is developing BAFF-R CAR-T therapy (PMB-CT01), an immunotherapy that targets the B-cell Activating Factor Receptor (BAFF-R) to address B-cell malignancies and autoimmune disorders. Unlike CD19-CAR T cell therapies, BAFF-R targeting is less susceptible to antigen loss-related relapse, offering a more durable response. The therapy involves genetically engineering a patient's T cells to express chimeric antigen receptors (CARs) that recognize and bind to BAFF-R on tumor cells. These modified T cells are then infused back into the patient to selectively target and eliminate BAFF-R-expressing malignant B cells. PeproMene Bio is also developing BAFF-R/CD3 bispecific antibodies (BiTEs) and allogeneic BAFFR CAR-NK cell therapies.
Target Audience
The primary target audience includes patients with relapsed or refractory B-cell malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and B-cell Non-Hodgkin’s lymphoma (B-NHL), as well as individuals with autoimmune disorders.
Features
- Utilizes a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R).
- Designed to overcome tumor relapse associated with antigen loss.
- PMB-CT01 is currently in Phase 1 clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell Non-Hodgkin’s lymphoma (B-NHL).
- Employs CAR-T cell technology to redirect T cells to target BAFF-R expressing tumor cells.
- Development of BAFF-R/CD3 bispecific antibodies (BiTEs) to redirect T cells to specific tumor antigens and activate T cells to kill tumor cells.
- Assessing partnerships to co-develop allogeneic BAFFR CAR-NK therapy.